• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deal search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
      • Deals search
      • Exits search
      • Funds search
      • Sponsors search
      • Advisers search
      • LPs search
      • League tables
      • Reports
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
UNQUOTE
  • Buyouts

CVC buys Cooper from Charterhouse for €2.2bn

  • Greg Gille
  • 12 March 2021
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

Charterhouse has entered exclusive negotiations for the sale of a majority stake in Cooper Consumer Health, a France-headquartered provider of generalist over-the-counter (OTC) self-care pharmaceuticals, to CVC Capital Partners.

The transaction is subject to workers' council information and consultation and to the approval of relevant regulatory authorities. Financials were not disclosed.

The deal values the business at €2.2bn, according to a source familiar with the situation, equating to a 14.1x entry multiple. CVC will be investing via CVC Capital Partners VII, which closed on €15.5bn in June 2017, though the firm closed its eighth-generation fund on €21.3bn in July 2020.

CVC teamed up with Vemedia founder Yvan Vindevogel and specialised healthcare fund Avista Capital Partners, as well as Cooper's management team, for the investment.

Successful completion of the sale would see Charterhouse reaping a money multiple of around 3x, returning in excess of €1.2bn to its investors, the source added.

The GP will reinvest in the business as part of the transaction, it said in a statement.

Unquote sister publication Mergermarket reported in mid-February that the selective sale process had moved to the second round, admitting BC Partners, CVC, OTPP and PAI, citing three sources familiar with the matter. PAI had teamed up with OTPP to bid for the business, according to the report.

Cooper was being sold based on EBITDA of €155m. Another option explored would have seen Charterhouse going down the recap route with a minority investor brought onboard, in a transaction similar to that of Curium, a Franco-American provider of nuclear medicine, Mergermarket reported. Rothschild was acting as sell-side adviser on the Cooper sale.

According to Unquote sister publication Debtwire, suitors for the hotly contested asset were considering leverage as high as 7.5x. The debt level was not far off from staple financing from sell-side bank HSBC, which was offering just over 7x through a first and second lien structure, the report added.

Previous funding
Charterhouse bought the pharmaceutical business from investment company Caravelle in 2016, having struck a deal in October 2015. The Cooper transaction was believed to be worth in the region of €700m, according to Unquote coverage at the time.

The transaction marked the first deal for Charterhouse Capital Partners X, which had held a first close on €1.5bn just prior to the investment. The fund ultimately closed on €2.3bn; its current performance stands at 1.7x for a net IRR of 18%.

Since the 2016 investment, Cooper was transformed from a purely French player to a pan-European business, Charterhouse said in a statement. It added that the company has more than doubled in size through a combination of organic growth and targeted M&A activity, with revenues now hitting €496m. This included the strategic acquisition and integration of international consumer health company Vemedia, an OTC branded product portfolio from Sanofi, alongside nine other add-ons.

Company
Founded in 1907, Cooper manufactures and distributes over-the-counter pharmaceuticals, including OTC medicines, dietary supplements and medical devices. The business has a direct presence in seven European markets and 30 export markets.

The company is headquartered in Paris. It generates turnover of €496m, against €215m at the time of the 2016 buyout, and a €155m EBITDA.

People
CVC - Michael Lavrysen, Victor Blanchard (senior managing directors).
Charterhouse - Vincent Pautet (partner).

Advisers
Vendors - Rothschild (M&A).

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Buyouts
  • Exits
  • France
  • Healthcare
  • CVC Capital Partners
  • Charterhouse Capital Partners
  • Secondary buyout
  • Exclusive

More on Buyouts

Permira to take Ergomed private for GBP 703m
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • Buyouts
  • 04 September 2023
Main Capital's Assessio to be sold to Pollen Street
Main Capital's Assessio to be sold to Pollen Street

Recruitment software company tripled in revenue under Main Capital’s ownership

  • Buyouts
  • 25 August 2023
TPG takes majority control of A-Gas, doubles down on impact investing
TPG takes majority control of A-Gas, doubles down on impact investing

KKR partially exits its 2017 investment in the specialty gas and chemical distributor, retaining a minority stake

  • Buyouts
  • 18 August 2023
Quadrivio to capitalise on baby boomers as it nears wrap for its new EUR 300m fund
Quadrivio to capitalise on baby boomers as it nears wrap for its new EUR 300m fund

The Silver Economy Fund makes its second investment as it highlights trend of GPs doubling down on narrow strategies

  • Buyouts
  • 16 August 2023

Latest News

Partners Group to release IMs for Civica sale in mid-September
  • Exits
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
BHM Group builds on PE strategy, eyes European medtech and renewable energy acquisitions
  • Investments
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Czech Republic-headquartered family office is targeting DACH and CEE region deals

  • 01 September 2023
Redalpine expands leadership team amid CHF 1bn-plus fundraise
  • Venture
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO

  • 31 August 2023
Change Ventures aims to hold final close for EUR 20m third fund by mid-2024
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds

  • 31 August 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013